Showing results (121-130 of 152) with videos related to

Sort By:
Pageof 16
Breast Cancer Research and Treatment|November 6, 2015
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancerAntonio Llombart-Cussac, Begoña Bermejo, Cristian Villanueva, et al.
Breast (Edinburgh, Scotland)|November 21, 2025
Health-related quality of life and fear of recurrence after early breast cancer treatment: Results from a cross-sectional surveyPaola Mosconi, Secondo Folli, Rosalba Miceli, et al.
Molecular Oncology|November 24, 2021
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trialTiziana Triulzi, Giampaolo Bianchini, Serena Di Cosimo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2019
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III TrialFrançoise Rothé, Maria Joao Silva, David Venet, et al.
European Journal of Cancer (Oxford, England : 1990)|July 9, 2019
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO studySerena Di Cosimo, Tiziana Triulzi, Sara Pizzamiglio, et al.
JAMA Oncology|October 7, 2021
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical TrialAntonio Llombart-Cussac, José Manuel Pérez-García, Meritxell Bellet, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Breast (Edinburgh, Scotland)|June 16, 2024
Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancerSerena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, et al.
The Lancet. Oncology|May 21, 2021
Chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trialJosé Manuel Pérez-García, Geraldine Gebhart, Manuel Ruiz Borrego, et al.
JAMA Oncology|September 30, 2016
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical TrialDebora Fumagalli, David Venet, Michail Ignatiadis, et al.
Pageof 16